A new study revealed that Lilly Biotechnology Center’s Alzheimer’s drug slowed the disease by as much as 22% to 35%, compared to a separate placebo study.
Read More New Alzheimer’s Drug Slows Early Stages Of DiseaseTag: Alzheimer's drug
FDA grants first full approval for an Alzheimer’s drug
For the first time in more than 20 years an Alzheimer’s medicine, from Eisai and Biogen (BIIB), has received standard FDA clearance.
Read More FDA grants first full approval for an Alzheimer’s drugDouble board-certified neurologist Dr. Russell Surasky on experimental Alzheimer’s drug
There is a promising new experimental drug available for those with Alzheimer’s, made by Eli Lilly. The company reports that in a late-stage trial, it slowed the progression of the disease by 35%. The Alzheimer’s Association predicts that the number of Americans living with Alzheimer’s will increase from over 6 million now to almost 13 million by 2050. Double Board Certified Neurologist,
Read More Double board-certified neurologist Dr. Russell Surasky on experimental Alzheimer’s drug